Skip to main content

Table 2 Knowledge of filariasis in the community

From: Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance

Variables Responses Male (N = 334) % (95% CI) Female (N = 357) % (95% CI) Total (N = 691) % (95% CI)
What is filariasis? Elephantiasis 61.6(65.4–74.8) 70.3(65.4–74.8) 67.8(64.3–71.3)
Lymphedema and elephantiasis 32.5(27.7–37.5) 29.1(24.6–34.0) 31.7(28.3–35.2)
Do not know 0.3(0.01–1.4) 0.56(0.1–1.70) 0.43(0.11–1.17)
Mode of transmission for filariasis? Mosquito bite 90.4(86.9–93.2) 85.4(81.5–88.8) 87.8(85.2–90.1)
Hereditary/contagious 8.7(6.0–12.0) 13.1(9.9–16.5) 11(8.8–13.5)
Do not know 0.9(0.22–2.42) 1.4(0.5–3.07) 1.15(0.54–2.2)
Most common symptoms Swelling of limbs 60.4(55.2–65.7) 34.0(29.1–39.0) 46.7(43.0–50.5)
Fever and swelling 38.6(33.5–44.0) 65.2(60.2–70.0) 52.4(48.6–56.1)
Do not know 0.9(0.22–2.42) 1.12(0.35–2.68) 1.0(0.44–2.0)
Treatment Medicine 90.1(86.5–93.0) 85.0(80.5–88.0) 87.3(84.6–89.6)
Not curable 8.9(6.25–12.42) 13.4(10.2–17.3) 11.3(9.1–13.8)
Do not know 0.9(0.22–2.42) 1.96(0.9–3.8) 1.4(0.7–2.56)
Knowledge regarding the distribution of filarial tablets for prevention Yes 95.5(92.9–97.4) 90.5(87.0–93.2) 92.9(90.8–94.6)
No 4.5(2.63–7.13) 9.5(6.8–12.9) 7.1(5.35–9.20)
Do you consider yourself to be at risk? Yes 86.5(82.5–89.9) 80.9(76.6–84.7) 83.6(80.7–86.3)
No 12.3(9.0–16.13) 17.08(13.4–21.2) 14.7(12.2–17.5)
Do not know 1.2(0.4–2.9) 1.96(0.9–3.8) 1.6(0.83–2.75)